AX

AxoGen IncNASDAQ AXGN Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.63

Micro

Exchange

XNAS - Nasdaq

AXGN Stock Analysis

AX

Uncovered

AxoGen Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

1/100

Low score

Market cap $B

0.63

Dividend yield

Shares outstanding

42.602 B

Axogen, Inc. is focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.

View Section: Eyestock Rating